The USFDA inspected the facility from 6th to 12th Februrary 2023.
The US Food Drug and Administration (USFDA) conducted inspection at FDC's manufacturing facility at B-8, MIDC Industrial Area, Waluj, Aurangabad, Maharashtra.The audit was carried out for the sterile ophthalmic products being marketed in the US. The audit concluded with "No observations" (Zero 483s).
FDC is principally engaged in the business of Pharmaceuticals. The company's consolidated net profit rose 14.2% to Rs 40.75 crore on 19.8% jump in net sales to Rs 409.30 crore in Q3 FY23 over Q3 FY22.
The scrip rose 0.87% to Rs 267.15 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app